BioLineRx. has filed a patent for a method of treating metastatic pancreatic adenocarcinoma. The method involves administering a peptide, an anti PD-1, and chemotherapy to the subject, post first-line treatment, to effectively treat the cancer. GlobalData’s report on BioLineRx gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights BioLineRx Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on BioLineRx, Peptide pharmacophores was a key innovation area identified from patents. BioLineRx's grant share as of September 2023 was 28%. Grant share is based on the ratio of number of grants to total number of patents.

Method of treating metastatic pancreatic adenocarcinoma using peptide, anti pd-1, and chemotherapy

Source: United States Patent and Trademark Office (USPTO). Credit: BioLineRx Ltd

A recently filed patent (Publication Number: US20230242644A1) describes a method for treating metastatic pancreatic adenocarcinoma in patients who have already undergone first-line treatment. The method involves administering a combination of a specific peptide (SEQ ID NO: 1), an anti PD-1 drug (specifically pembrolizumab), and a chemotherapy regimen.

The chemotherapy regimen mentioned in the patent includes multiple chemotherapeutic agents, specifically irinotecan, fluorouracil (5-FU), and leucovorin (LV). The irinotecan is liposome-encapsulated, which may enhance its effectiveness.

The peptide is administered subcutaneously (SC) at a dose of 1.25 mg/kg. The anti PD-1 drug, pembrolizumab, is administered intravenously (IV). The chemotherapy is also administered intravenously.

The treatment protocol described in the patent involves a monotherapy period with the peptide on Days 1-5, followed by a combination therapy with the peptide, anti PD-1, and chemotherapy. The combination therapy is repeated every 2 weeks with the chemotherapy and every 3 weeks with the anti PD-1 drug.

It is important to note that the claims in the patent are specific to treating metastatic pancreatic adenocarcinoma in patients who have already undergone first-line treatment. The method described in the patent involves a combination of the peptide, anti PD-1 drug pembrolizumab, and a specific chemotherapy regimen. The patent also provides details on the administration routes, dosages, and treatment schedule.

This patent filing may be of interest to researchers, clinicians, and pharmaceutical companies involved in the development and treatment of metastatic pancreatic adenocarcinoma. The combination therapy described in the patent has the potential to improve outcomes for patients who have already undergone first-line treatment for this aggressive form of cancer. However, further research and clinical trials would be necessary to validate the efficacy and safety of this treatment method.

To know more about GlobalData’s detailed insights on BioLineRx, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies